Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunomodulation via suppression of peripheral blood mononuclear cell activation and proliferation
- Molecular classification
- Cell signaling pathway, Immunomodulatory agent target, Cytokine signaling pathway modulator
01
Overview
This target encompasses diverse molecular pathways aimed at reducing inappropriate immune system activity by limiting both initiation signals (activation) and subsequent clonal expansion (proliferation) among circulating mononuclear effector populations. It involves modulation of PBMC activity via soluble factors, cellular interactions, and checkpoint molecules, relevant for autoimmune diseases, transplant medicine, and cancer.
- Other names
- PBMC activation suppressionPBMC proliferation suppressionPeripheral blood mononuclear cell immunomodulationT cell suppressionB cell suppressionMonocyte suppressionLymphocyte suppression
02
Mechanism of action
Inhibition of PBMC activation and proliferation through various mechanisms, including soluble mediators, cell-cell interactions (e.g., Tregs), and checkpoint inhibition (e.g., PD-1/PD-L1)
03
Biological functions
Immune response modulationInflammation regulationT cell regulationB cell regulationMonocyte regulationCell proliferation inhibitionCell activation inhibition
04
Disease associations
Autoimmune diseasesTransplant rejectionCancerInflammatory diseases
05
Safety considerations
Increased risk of infectionPotential for immune suppression-related adverse eventsOff-target effects on other immune cellsCytokine release syndrome
06
Interacting drugs
Monoclonal antibodies (anti-CD3, anti-CD20, etc.)
3 more in the full profile.
07
Biomarkers
PBMC proliferation rateCytokine levels (IL-2, IFN-gamma, IL-10)Expression of activation markers (CD69, CD25)Regulatory T cell (Treg) frequencyExpression of checkpoint molecules (PD-1, CTLA-4)
Beyond the preview
Go deeper on Immunomodulation via suppression of peripheral blood mononuclear cell activation and proliferation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunomodulation via suppression of peripheral blood mononuclear cell activation and proliferation.